Latest bevacizumab News

Pharmac funding decision will increase medicines access
FivepHusion secures ethics approval of a Phase 1b deflexifol clinical trial
PBS Changes From 1 October
FivepHusion announces ethics approval of Phase 1b trial of deflexifol as first-line treatment
Imfinzi plus transarterial chemoembolisation (TACE) and bevacizumab reduced the risk of disease progression or death by 23% vs. TACE in liver cancer…
Allarity Therapeutics and FivepHusion announce collaboration for the development of Deflexifol with DRP Companion Diagnostics
Lynparza and Imfinzi combination reduced risk of disease progression or death by 37% vs. chemotherapy and bevacizumab in patients with advanced ovarian…
Lynparza and Imfinzi combination improved progression-free survival in newly diagnosed patients with advanced ovarian cancer without tumour BRCA mutations in DUO-O Phase III trial
Lynparza in combination with bevacizumab, and as monotherapy, demonstrates clinically meaningful survival benefit
AstraZeneca aims to transform cancer outcomes with new data across industry-leading portfolio at ESMO 2022
Alvotech and Cipla Gulf Enter Into a Partnership for Commercialization of Key Biosimilar